Remove Clinical Trials Remove FDA Approval Remove Gene Remove Gene Expression
article thumbnail

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

CAMP4’s CSO David Bumcrot PhD tells Pharmaceutical Technology that the company plans to see clinical trials go forward for their urea cycle disorder programs late next year. The most common marketed drugs in this space aim to address the hyperammonaemia caused by the defective genes in this disorder.

RNA 245
article thumbnail

Eli Lilly’s Olumiant Wins FDA Approval as First Systemic Treatment for Alopecia Areata

XTalks

Eli Lilly’s Olumiant (baricitinib) has won US Food and Drug Administration (FDA) approval as the first systemic treatment for severe alopecia areata (AA), an autoimmune disorder that leads to patchy baldness. The Olumiant approval is therefore a big win as it helps fulfill a significant unmet need in the area.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Data dive finds cheap diuretic could be Alzheimer’s drug

pharmaphorum

Bumetanide’s potential was discovered by analysing data on more than 1,300 FDA-approved drugs derived from brain tissue samples, laboratory experiments involving animal and human cells, and human population studies.

article thumbnail

Vtama (tapinarof) Cream Gains FDA Approval for the Treatment of Plaque Psoriasis in Adults

XTalks

XTALKS WEBINAR: All Means All: The Road to Inclusivity in Clinical Trials. Register for this free webinar to learn what the FDA’s new draft guidance means for diverse and inclusive trials. Clinical Trials of Vtama. Live and On-Demand: Tuesday, July 12, 2022, at 11am EDT (4pm BST/UK).

article thumbnail

Artificial intelligence could be new blueprint for precision drug discovery

The Pharma Data

online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval. “Academic labs and pharmaceutical and? Nature Communications, 2021.

Drugs 52
article thumbnail

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

XTalks

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. CRISPR Gene Editing Inventors Win Nobel Prize.

article thumbnail

Disruptive Technologies and Mature Regulatory Environment Vital for Cell Therapy Maturation

The Pharma Data

Immuno-oncology and CAR T cells energized the field of regenerative medicine, but for cell and gene to deliver on their promises, new, disruptive technologies and new modes of operation are needed. As with dry AMD, there is no FDA-approved therapy. “We Other cell and gene companies are advancing solutions, too.